HOT STOCKS 100% 200% 300% profits possible short term Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : HOT STOCKS 100% 200% 300% profits possible short term

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bram12345 who wrote (1240)	9/16/1998 7:44:00 PM
From: R>G>	Read Replies (2) of 2038

Sangunie, SGNC to be on CNNfn 9/21/98 8:30 PM ET Sangunie is in the synthetic blood industry. Thomas C. Drees, Ph.D., M.B.A. is the chairman and CEO. He will be televised from 8:30-9:00 on Monday. The 1/2 hour program will focus on Sanguine, its product and the synthetic blood industry. Sangunie is filing with SEC Battelle is doing research and soon to start animal testing. This is a 2nd generation drug, the 1st generation drug had received FDA approval. Presently there are 60 million transfusions done per year. Average transfusion requires 2 pints. That's 120 million pints per year. Sanguine plans to sell product for $300.00 per pint. For more information please see R>G>s unofficial SGNC webpage members.aol.com R>G>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next